U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07862075) titled 'Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis' on Sept. 20.
Brief Summary: Autoimmune pancreatitis (AIP) is an immune-related inflammatory disease of the pancreas. Relapse can occur after treatment, and long-term treatment with glucocorticoids and conventional immunosuppressants can cause significant side effects.
This multicenter, single-arm, open-label study aims to evaluate the efficacy and safety of inebilizumab in patients with AIP. Inebilizumab targets CD19 and reduces B cells, including plasmablasts.
The study plans to enroll 50 patients with confirmed AIP, including both newly diagnosed pati...